triptorelin pamoate (Decapeptyl SR 22.5mg)

following an abbreviated submission

triptorelin pamoate 22.5mg (Decapeptyl SR®) is accepted for use within NHS Scotland.

Indication under review:

•Treatment of patients with locally advanced, non-metastatic prostate cancer, as an alternative to surgical castration.
•Treatment of metastatic prostate cancer.

This new preparation of triptorelin allows 6-monthly administration (as triptorelin pamoate in a 22.5mg dose). Triptorelin 11.25mg (as acetate) is administered every 3 months and has previously been accepted by SMC. Bioequivalence of the pamoate and acetate salts has been demonstrated  and the new preparation is cost neutral.

Note: The indication for triptorelin 11.25mg formulation was reworded in 2007 to achieve consistency Europe-wide and now reads as per the indication for triptorelin 22.5mg.